---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-24-000147"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:21:54.422074+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment

## Summary
- Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.
- R&D expenses $75.5M, up 49% YoY, driven by IMVT-1402 prep and batoclimab trials.
- Completed enrollment in batoclimab pivotal MG trial; top-line results expected by March 31, 2025.
- Plans to initiate 4-5 potentially registrational programs for IMVT-1402 by March 31, 2025; 3 IND applications active by end-2024.
- Graves' disease program update expected fall 2024; batoclimab TED top-line data in H1 2025.

## SEC filing metadata
- accession: 0001764013-24-000147
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000147/0001764013-24-000147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000147/imvt-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-24-000147
- JSON: https://secwatch.observer/filing/0001764013-24-000147.json
- Plain text: https://secwatch.observer/filing/0001764013-24-000147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.